Behavioral therapy to enable women with urge incontinence to discontinue drug treatment: A randomized trial

University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Annals of internal medicine (Impact Factor: 17.81). 08/2008; 149(3):161-9.
Source: PubMed


Women with urge urinary incontinence are commonly treated with antimuscarinic medications, but many discontinue therapy.
To determine whether combining antimuscarinic drug therapy with supervised behavioral training, compared with drug therapy alone, improves the ability of women with urge incontinence to achieve clinically important reductions in incontinence episodes and to sustain these improvements after discontinuing drug therapy.
2-stage, multicenter, randomized clinical trial conducted from July 2004 to January 2006.
9 university-affiliated outpatient clinics.
307 women with urge-predominant incontinence.
10 weeks of open-label, extended-release tolterodine alone (n = 153) or combined with behavioral training (n = 154), followed by discontinuation of therapy and follow-up at 8 months.
The primary outcome, measured at 8 months, was no receipt of drugs or other therapy for urge incontinence and a 70% or greater reduction in frequency of incontinence episodes. Secondary outcomes were reduction in incontinence, self-reported satisfaction and improvement, and scores on validated questionnaires measuring symptom distress and bother and health-related quality of life. Study staff who performed outcome evaluations, but not participants and interventionists, were blinded to group assignment.
237 participants completed the trial. According to life-table estimates, the rate of successful discontinuation of therapy at 8 months was the same in the combination therapy and drug therapy alone groups (41% in both groups; difference, 0 percentage points [95% CI, -12 to 12 percentage points]). A higher proportion of participants who received combination therapy than drug therapy alone achieved a 70% or greater reduction in incontinence at 10 weeks (69% vs. 58%; difference, 11 percentage points [CI, -0.3 to 22.1 percentage points]). Combination therapy yielded better outcomes over time on the Urogenital Distress Inventory and the Overactive Bladder Questionnaire (both P <0.001) at both time points for patient satisfaction and perceived improvement but not health-related quality of life. Adverse events were uncommon (12 events in 6 participants [3 in each group]).
Behavioral therapy components (daily bladder diary and recommendations for fluid management) in the group receiving drug therapy alone may have attenuated between-group differences. Assigned treatment was completed by 68% of participants, whereas 8-month outcome status was assessed on 77%.
The addition of behavioral training to drug therapy may reduce incontinence frequency during active treatment but does not improve the ability to discontinue drug therapy and maintain improvement in urinary incontinence. Combination therapy has a beneficial effect on patient satisfaction, perceived improvement, and reduction of other bladder symptoms.

Download full-text


Available from: Mary P Fitzgerald
  • [Show abstract] [Hide abstract]
    ABSTRACT: Overactive bladder (OAB) is a disorder characterized by urinary urgency. In the past, the pathophysiology and treatment of OAB focused on the parasympathetic efferent innervation of detrusor smooth muscle cells. However, recent evidence has provided a clearer understanding of the neurological, chemical, and functional physiology of the bladder and how it relates to the pathophysiology of OAB. Urothelial cells, sensory neurons, and interstitial cells of Cajal have secretory and receptor functions that play an important role in bladder function and dysfunction. As we learn more about bladder function and the mechanism of current OAB treatments, newer forms of therapy are emerging. These include neuromodulation, botulinum toxin, and the development of new drugs based on the pathophysiology of OAB. KeywordsOveractive bladder-Detrusor overactivity-Bladder pathophysiology-Urothelium-Interstitial cells of Cajal-Neuromodulation-Botulinum toxin-Anticholinergics
    No preview · Article · Sep 2010 · Current Bladder Dysfunction Reports
  • [Show abstract] [Hide abstract]
    ABSTRACT: For several decades, biofeedback has been utilized to help patients gain control of urinary problems. First described in the 1950s, pelvic floor muscle training employing biofeedback techniques has re-emerged as many patients seek to improve their urinary symptoms without medications or invasive procedures. Developing evidence and clinical agreement suggest that the pelvic floor musculature plays an important and often overlooked role in the etiology of lower urinary tract symptoms. New techniques involving computerized visual feedback and electrical stimulation or magnetic stimulation seek to improve the efficacy of pelvic floor muscle exercises. However, findings from the literature for increased response to these exercises with intensity of biofeedback programs are conflicting. While they pose few risks or side effects, biofeedback programs are a time-consuming exercise for patients and providers. As we explore the promising role of pelvic floor rehabilitation in treatment of pelvic floor disorders, we must continue to assess the efficacy and cost-effectiveness of biofeedback as an adjunct to pelvic floor muscle exercises.
    No preview · Article · Mar 2012 · Current Bladder Dysfunction Reports
  • [Show abstract] [Hide abstract]
    ABSTRACT: Urodynamic studies (UDS) have been used to objectively characterize a patient’s complaint of urinary incontinence. Presumably, the clinician can utilize the UDS data to guide treatment options. It is even hoped that UDS can help predict which treatments should be utilized to produce the most effective outcomes. However, is this currently the case? The Urinary Incontinence Treatment Network (UITN) has completed four large randomized clinical trials related to treatments for urinary incontinence. Two trials compared outcomes of different surgeries for stress urinary incontinence (SUI) in which standardized UDS protocols were used. Secondary analyses of these UDS data showed that UDS were neither prognostic of treatment outcomes nor correlative with severity of UI symptoms, suggesting limited utility of UDS in the evaluation and management of the uncomplicated SUI patient. A third trial was designed to answer whether a basic office examination is not noninferior to UDS in affecting SUI surgical outcomes. The results of this study are currently in press. A fourth trial examined treatment of urgency urinary incontinence (UUI). Because UDS was not part of this trial, the utility of UDS in management and treatment of UUI could not be assessed. In summary, UDS will need to undergo further refinements to increase its clinical effectiveness in the area of urinary incontinence.
    No preview · Article · Sep 2012 · Current Bladder Dysfunction Reports
Show more